Table 3.
Change in the impact of French Alzheimer disease research between the periods 2004–2008 and 2009–2013, as assessed by research output and representation in the top 1 % globally cited articles compared with French scientific output in stroke, Parkinson disease, HIV, and diabetes
| Research output (% France’s share of output) | Output relative increase (fold change) | France’s share of top 1 % globally cited articles | Top 1 % relative increase (fold change) | |||
|---|---|---|---|---|---|---|
| 2004–2008 | 2009–2013 | 2004–2008 | 2009–2013 | |||
| Alzheimer disease | 1, 082 (0.4 %) | 1, 836 (0.6 %) | 3.9 | 18 (0.7 %) | 44 (1.1 %) | 2.3 |
| Diabetes | 2, 890 (1.1 %) | 3, 725 (1.2 %) | 1.6 | 75 (3.0 %) | 130 (3.2 %) | 1.2 |
| HIV | 3, 092 (1.1 %) | 3, 297 (1.0 %) | 0.4 | 43 (1.7 %) | 58 (1.4 %) | 0.6 |
| Parkinson disease | 997 (0.4 %) | 1, 281 (0.4 %) | 1.6 | 17 (0.7 %) | 21 (0.5 %) | 0.4 |
| Stroke | 1, 495 (0.5 %) | 2, 264 (0.7 %) | 2.9 | 46 (1.8 %) | 98 (2.0 %) | 1.8 |
| Overall | 270, 314 | 318, 946 | 1 | 2, 496 | 4, 041 | 1 |